Skrivánková B, Julis I, Podrazký V, Trnavský K
Institute of Rheumatology, Praha, Czechoslovakia.
Agents Actions Suppl. 1993;39:219-24.
The effect of glycosaminoglycan-peptide complex (GPC) (Rumalon, made by Robapharm, Switzerland) on cells of the inflammatory periarticular infiltrate and on the articular chondrocytes was studied in experimentally induced papain arthropathy by means of image cytometry and biochemistry. The GPC therapy exhibited some antiinflammatory effect as documented by the reduction of DNA proliferative activity in the inflammatory infiltrate and lowered the activity of hydrolytic enzymes and enzyme inhibitors detected in chondrocytes.
通过图像细胞术和生物化学方法，在实验性木瓜蛋白酶诱导的关节病中，研究了糖胺聚糖 - 肽复合物（GPC）（Rumalon，由瑞士Robapharm公司生产）对炎性关节周围浸润细胞和关节软骨细胞的影响。GPC治疗表现出一定的抗炎作用，这可通过炎性浸润中DNA增殖活性的降低以及软骨细胞中检测到的水解酶和酶抑制剂活性的降低来证明。
